The cytomegalovirus (CMV) treatment industry is at the forefront of tackling a formidable viral foe that frequently goes unchecked. HIV-positive persons and transplant recipients are among the groups of people whose immune systems are compromised by the herpesvirus cytomegalovirus, which can be very deadly. The development of effective therapies has therefore grown to be a …